CRISPR patent ruling has little impact in laboratory setting, MIT researchers say – The Tech
|
CRISPR patent ruling has little impact in laboratory setting, MIT researchers say
The Tech Researchers at MIT maintained that the U.S. Patent Trial and Appeal Board’s Feb. 15 decision, which affirmed the Broad Institute’s patent claims on using CRISPR-Cas9 technology to edit eukaryotic genomes, had little impact on future laboratory research. |
KABC-TV |
CAR T-cell therapy turns blood cells into cancer fighters
KABC-TV Researchers have moved forward with a gene therapy that turns a patient’s blood cells into cancer fighters. In a major study, a third of lymphoma patients had no signs of the disease six months after treatment. The potential game-changer is called CAR … Kite’s CAR T-Cell Therapy SuccessThe Scientist With Eye On FDA, Kite Says CAR–T For Lymphoma Holds Up After 6 MonthsXconomy New gene therapy turns blood cells into cancer fighters6abc.com STAT –TheStreet.com –Seeking Alpha all 258 news articles » |
Bioscience Technology |
Gene Therapy Offers Hope for Newborns with Severe Immune Disorder
Bioscience Technology Infants born with a type of the devastating immune disorder SCID, or “bubble boy disease,” may have the option of a novel gene therapy treatment, thanks to a clinical trial at UCSF Benioff Children’s Hospital San Francisco. The trial is funded by a … |
|
ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
P&T Community ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. The HDM … |